- Accueil
 - FR
 - Étudier
 - Offre de formation
 - fcsante
 
- 
            
            Partager cette page
 
PHARMED - Post-graduate program in Pharmaceutical Development Sciences
Accroche introductive
Post-graduate program in Pharmaceutical Development Sciences.Accéder aux sections de la fiche
Call to actions
- 
                            Intitulé du programmePHARMED - Post-graduate program in Pharmaceutical Development Sciences
 - 
                            mnémonique du programmeFC-704
 - 
                                Programme organisé par
- Centre de Formation Continue en Santé et Sciences de la vie
 - Faculté de Médecine
 
 - 
                            Type de titreformation continue
 - 
                                Secteur et domaine d'étudesSciences, technologie, santé/Médecine et Santé
 - 
                                Accessible en reprise d'étudesoui
 - 
                                Type d'horaireEn journée
 - 
                                Langues d'enseignementanglais
 - 
                            Durée de la formationlongue (plus de 15 jours)
 - 
                                CampusAutre campus
 - 
                                Catégorie / ThématiqueSanté - Sciences biomédicales et pharmaceutiques
 - 
                                            ComplémentMarie LEBACQ
ULB HeLSci - BIOPS Training engineer 
- 
						E-mail de contact
 - 
						Téléphone de contact
 - 
						Renseignements supplémentaires
 
Présentation
Détails
Informations générales
Type de titreformation continue
Durée de la formationlongue (plus de 15 jours)
Langue(s) d'enseignementanglais
Type d'horaireEn journée
CampusAutre campus
Catégorie(s) - Thématique(s)Santé - Sciences biomédicales et pharmaceutiques
Faculté(s) et université(s) organisatrice(s) Accessible en reprise d'étudesoui
Présentation
Objectifs de la formation
Horaire
En journée
- Each module is divided into several 3-hours courses that are given remotely via video conference in English, on Tuesday, Thursday or Friday afternoon.
 - The whole program is spread over 2 years with an average of 5 courses of three hours by month (from January to June and from September to December). Start in January 2025 !
 
Register now !
Les + de la formation
- International program
 - Distance learning
 - A seventh elective module with a specific theme
 - The teaching team is composed of experts from various universities, regulatory authorities/agencies, CROs, pharmaceutical and biotechnology companies
 
Calendrier & inscriptions
Public ciblé
- Intended for those who want to train for a future career in the pharmaceutical industry as well as for employees of biopharmaceutical companies who wish to complement or update their knowledge
 
Calendrier & inscriptions
Programme
Module 1 : Drug development with a focus on the changing health care environment
1- Setting the scene : the context of drug development
- Overview and drivers of pharmaceutical innovation
 - Specificities of the pharmaceutical market
 - Changes in the healthcare environment
 
2- Integrated product development : from discovery phase to market authorization
- Overview of the process of drug development
 - How to achieve marketing approval and commercial excellence in a changing health care environment ?
 - Evolution from blockbuster to personalized medicine
 - The rising importance of orphan drugs
 - Patenting : basic criteria, issues in a changing health care environment and open-innovation
 
3- Drug screening : from animals to recombinant proteins and translational research
- Testing in animals : current use, ethical and regulatory aspects, limits ans alternative approachs
 - Evolution of the methods used for drug screening
 - High-Throughput-Screening (HTC) : Steps involved in setting-up of new functional assays
 - HTC : Robustness, troughput and quality of assays
 - System biology and principles of translational research
 
4- Big data and personnalized medicine : How AI can potentially reinvent the drug design and development ?
- Concept of personalized medicine
 - Patient selection
 - AI for Clinical Trial design
 - Big data, Robots and AI in Medecine and Healthcare
 - Impact on drug development and marketing
 - AI in Medecine
 
Module 2 : From pre-clinical to First-in-Human studies  
 
1- Pre-clinical strategy and Study design
- GLP and Pre-clinical testing requirements
 - Stages of development and registration
 - Study protocol design
 - Pre-clinical strategy : time and costs analysis
 - Special population requirements and Regulatory Compliance
 
2- Pre-clinical safety : Principles of pharmacology and toxicology
- Drug metabolism, Pharmacokinetics (ADME) and Pharmacodynamics : basic concepts
 - How to choose the dose for first in human administration ?
 - Toxicology testing : general toxicology, genotoxicity, carcinogenicity
 - Genetic and genomic factors in drug development and drug response
 - Novel approaches in investigative toxicology
 - In silico toxicology methods : applications
 
3- Drug formulation
- Main apsects of drug formulation
 - Concept of drug bioavailability
 - Non-conventional dosage forms : oral sustained release dosage forms, transdermal forms, injectable biodegradables microspheres, etc
 - Nanotechnologies for drug delivery : potential and challenges
 - 3D printing (drugs and medical devices) : what is possible to do now ?
 
4- Manufacturing
- Pharmaceutical technical development : formulations, primary packaging, delivery system
 - Quality Management System, Quality by design and Process Analytical Technologies
 - GMPs and Required structures of departments/systems in development and manufacturing
 - EMA and FDA agencies and inspection-operating environment for product development and manufacturing (concept of inspection readiness)
 
5- Moving to First-in-Human studies
- Ethics in the Pharmaceutical Industry
 - Requirements, ethics and regulations of First-in-Human studies
 - Accelerating the move to clinical trials (possibilities and opportunities of computer assisted modelling on the way of proof of concept)
 - Strategic importance and practical organization of Phase I studies (responsibilities, planning and activities)
 
Module 3 :Clinical studies : Planning, managing and collecting data
1- Early studies in patients
- Dose-finding studies
 - Proof of mechanism studies
 - Bioequivalence testing
 - Clinical Pharmacokinetics and Pharmacodynamics
 - Confirmatory clinical development plan
 
2- Clinical trials Designs
- Different types of clinical trials : study designs
 - Randomisation modes
 - Statistical aspects in the planning of clinical trials (choice of the enpoints, hypothesis, Alpha and Beta risks, sample size calculation)
 - Innovative study designs
 
3- Planning and managing clinical trials
- Regulatory aspects troughout the product development cycle (GCP requirements)
 - Set-up of clinical trial
 - Monitoring safety in clinical trials and Drug Development
 - Development Risk Management Plans – The challenges
 - Risk-based and remote monitoring in clinical trials
 - Patient centric approach : Direct-to-patients trials and logistics
 - Outsourcing of clinical trials and contrat management
 - Audits in clinical trials : Key feature of audits and inspections, keys to preparing for and effectively managing inspection, roles and expectations of key personnel, differences between inspections from various authorities
 
4- Collecting clinical trials data
- Clinical trial data collection and data management
 - Patient adherence and persistence in trials (uptake of mobile health, e-tools, big data analysis and personnalized medicine)
 
5- Blockchain in Clinical trials
- Hope or reality ?
 - Cases for blockchain application in clinical trials
 - Barriers and challenges yet to be resolved
 
Module 4 : Data Evaluation and Biostatistics
1- Clinical trial protocol and Investigator drug brochure (IDB)
- Clinical trial protocol : a key document
 - Reading and understanding a clinicial trial protocol
 - Role of the Ivestigator Drug Brochure (IDB)
 - Regulatory codes and guidance for authoring the IDB
 
2- Biostatistics : Clinical data Evaluation
- Statistical methods used in clinical research
 - Common errors in statistics and how avoid them
 - Critical reading of a scientific publication on biostatistics
 - Understanding the crisis around the p-value : Statistical methods for the 21st century
 
3- Safety data Evaluation
- Methods for the evaluation of Safety Data in clinical trials
 - Background and implementation of Development Safety Update Reports (DSUR)
 - Data Safety Monitoring boards
 
4- Data Interpretation and Scientific writing
- Different aspects of the Clinical study report : data and conclusions on paper
 - Preparation of review documents for regulatory submissions
 - Writing a manuscript for publication
 - Submission to a peer-review journal, dealing with the reviewer’s comments
 
Module 5 : Registration and Pharmacovigilance
1- Drug Registration : European procedures and International environment
- Overview of the regulatory environment and medicines registration in the EU
 - Comparison with the US FDA requirements and Japanese authorities
 - Comparison with requirements in international and emerging-markets
 - The Common Technical Document (CTD) format
 - Special issues : orphan products
 - Understanding defects in the application and improving the chances of approval
 - Collaborate with the FDA to facilitate innovation
 
2- Pharmacovigilance & Medical information
- Back to basics in Pharmacovigilance
 - EU regulations and Guidelines in Pharmacovigilance
 - Pharmacovigilance in daily practice
 - Overview of Patient Support ProgramS (PSPS)
 - Recent trends in Pharmacovigilance
 - Medical information : communication with health practitioners
 - Summary of products characteristics and user package leaflet
 
3- Pharmacoepidemiology
- Principles of pharmacoepidemiology
 - Study methods and data ressources
 - Interpretation of pharmacoepidemiological data
 - Role of the pharmacoepidemiology in the lifecycle of a medicine
 
Module 6 : Health Economic and Biopharmaceutical market
1- Principles and practical applications of health economics
- Health Economic Evaluation of medicinal products : concept of study quality and the methods used to assess quality
 - Health technology assessment
 - Interpretation of the cost-effectiveness plane
 - Impact of the economic evaluation in the field of market access
 - Pricing and reimbursement of medicinal products (overview, issues and challenges in EU)
 - Patient reported outcomes – Real world data and Real world evidence
 
2- Market access
- Ethical and legal aspects
 - Macroeconomic aspects
 - Medical affairs, regulatory environment and market access in emerging markets
 - Pharmaceutical marketing : lifecycle of a medicinal product, trademark, business model
 
3- Innovation and improvement of health care
- Which new products are really innovative ?
 - Health data bases for innovation and improving health care
 
Elective modules
Biologics, Vaccines, ATMPs, Medical advices : how do they differ from conventional drugs ?
- Specificities of the clinical development of Biologics
 - Medical advices : Overview from manufacturer to patient
 - Advanced Therapy Medicinal Products (ATMPs)
 - Vaccines development challenges : from preclinical to clinical studies
 
